
BiomX Inc. (PHGE) Stock Forecast & Price Target
BiomX Inc. (PHGE) Analyst Ratings
Bulls say
BiomX Inc. is advancing its pipeline of phage-based therapies, with encouraging results from its BX211 Phase 2 trial for diabetic foot osteomyelitis indicating positive trends in clinical parameters, such as reduced infection and improved resolution as evidenced by imaging studies. The Company also received favorable feedback from the FDA regarding its BX011 multi-phage cocktail, which is set to enter a Phase 2a study, targeting multiple efficacy endpoints that could enhance lung function and quality of life in cystic fibrosis patients. Furthermore, the potential for increased market penetration and the addition of indications in various stages of development, along with broader accessibility beyond the U.S., positions BiomX for significant upside in valuation and commercial success.
Bears say
BiomX Inc. faces a negative outlook primarily due to investor sentiment shifting unfavorably following recent clinical trial results, notably as key endpoints achieved statistical significance but others narrowly missed the conventional threshold. Additionally, the company may encounter significant challenges, including the potential for failed or inconclusive clinical trials, difficulty in securing adequate funding for drug development, and the risk of dilutive capital raises. The culmination of these factors, alongside concerns regarding the commercial viability of its products, raises substantial uncertainties about the future performance of BiomX's stock.
This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.
BiomX Inc. (PHGE) Analyst Forecast & Price Prediction
Start investing in BiomX Inc. (PHGE)
Order type
Buy in
Order amount
Est. shares
0 shares